AllianzGI Convertible & Income Fund II About To Put More Money In Your Pocket (NCZ)

Looking at the universe of stocks we cover at Dividend Channel, on 2/11/14, AllianzGI Convertible & Income Fund II (NCZ) will trade ex-dividend, for its monthly dividend of $0.085, payable on 3/3/14. As a percentage of NCZ's recent stock price of $9.54, this dividend works out to approximately 0.89%, so look for shares of AllianzGI Convertible & Income Fund II to trade 0.89% lower — all else being equal — when NCZ shares open for trading on 2/11/14.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for NCZ, showing historical dividends prior to the most recent $0.085 declared by AllianzGI Convertible & Income Fund II:

NCZ+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from NCZ is likely to continue, and whether the current estimated yield of 10.70% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of NCZ shares, versus its 200 day moving average:

AllianzGI Convertible & Income Fund II 200 Day Moving Average Chart

Looking at the chart above, NCZ's low point in its 52 week range is $8.11 per share, with $9.75 as the 52 week high point — that compares with a last trade of $9.53.

In Friday trading, AllianzGI Convertible & Income Fund II shares are currently up about 0.2% on the day.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says